Prescient Therapeutics (FRA:UDD) GF Score: 22/100 (As of Jul. 05, 2026) — Near Median


FRA:UDD Prescient Therapeutics Ltd FRA:UDD
22 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Prescient Therapeutics GF Score?

Prescient Therapeutics FRA:UDD +1.64% 22 GF Score is 22 as of Jul. 05, 2026, which is at its 10-year median of 22.00. GuruFocus rates FRA:UDD with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Prescient Therapeutics has the GF Score of 22, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Prescient Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Prescient Therapeutics  (FRA:UDD) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Prescient Therapeutics GF Score Related Terms

FRA:UDD vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Prescient Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prescient Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's GF Score falls into.


FRA:UDD
22GF Score
Prescient Therapeutics Ltd FRA:UDD
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 22 mean?
Prescient Therapeutics (FRA:UDD) has a GF Score of 22 as of Jul. 05, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Prescient Therapeutics and its competitors. This is near median its historical median of 22.00. Over the past decade, Prescient Therapeutics' GF Score has ranged from 18.00 to 40.00.
Is Prescient Therapeutics' GF Score too high?
Prescient Therapeutics' current GF Score of 22 is near median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 18.00 to a high of 40.00. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' GF Score compare to VRTX and REGN?
Prescient Therapeutics' GF Score of 22 can be compared against companies in the Biotechnology industry. Historically, Prescient Therapeutics' own GF Score has ranged from 18.00 to 40.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current GF Score is 22, which is near median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current GF Score of 22. The current GF Score is 22, which is near median its 10-year median of 22.00. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current GF Score is 22 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score

Get the complete analysis for FRA:UDD

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price